


Please amend claims 8 and 15 and add new claims 19 to 25 as follows before calculating the filing fee for the above-identified application:

8. (Amended) Process for the preparation of a compound of formula (I) according to [any one of] Claim[s] 1 [to 5 and 7], ^{wherein} characterized in that:

(1) either when $Z = NR_{11}R_{12}$, in which R_{11} and R_{12} are as defined for (1):


(1a) when at least one of the R_{11} and R_{12} radicals is different from hydrogen, a compound of formula:



in which R_1 , R_2 , R_3 , R_4 , W , Cy and T are as defined for (I) and in which X is a halogen or a sulphonic acid derivative is reacted with a derivative of formula ZH in a solvent selected from dimethylformamide, tetrahydrofuran or acetonitrile, at temperatures of between 0° and $120^\circ C$;

(1b) when R_{11} and $R_{12} = H$, the compound (IIA), in which X is an azido, is reduced to amino;

(2) or, when $Z = -COOH$, a compound of formula:




in which R_1 , R_2 , W , R_3 , R_4 and Cy are as defined for (I) and T' represents $T-CH_2-$, is oxidized in an acid solvent at a temperature of between $0^\circ C$ and $100^\circ C$, alkali metal dichromates or alkali metal or alkaline-earth metal permanganates;


(3) or a compound of formula:

81

882740-006T5060




in which R_1 , R_2 , Cy, T and Z are as defined for (I), is reacted with a compound of formula:




in which W, R_3 and R_4 are as defined for (I) and Hal represents a halogen atom, in an anhydrous solvent in the presence of a metal hydride or an alkali metal alkoxide at temperatures of between -40° and 25°C ;

(4) or, when $Z = -\text{COOH}$, a compound of formula:




in which R_1 , R_2 and Cy are as defined above for (I) and T' represents $T-\text{CH}_2$, is oxidized [to (I)], then the acid thus obtained of formula:



in which R_1 , R_2 , Cy and T are as defined above for (I), is subsequently optionally protected by a protective group for the carboxylic acid, in order to obtain the intermediate of formula:

82

00051900-04198
00051900-04198



in which R₁, R₂, Cy and T are as defined for (I) and P represents a protective group chosen from an alkyl, a *tert*-butyl or a benzyl, and, finally, this compound (II' BP) is subjected to the action of a derivative of formula (2) in order to obtain, after deprotection, a compound (I); one of its quaternary ammoniums, oxides, sulphones or salts.

14
15. (Amended) Pharmaceutical composition according to [any one of] Claim[s] 8 [to 14] also containing another active principle.

Please add the following new claims:

18. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.--

19
20. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 2.--

20
21. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 3.--

21
22. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 4.--

22
23. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 5.--

83